Programm Herausforderungen in der Augenheilkunde 109. DOG ...

58 Wissenschaftliches Programm
Scientific Program
Estrel Saal A & B Freitag Friday 30.9.2011
8:00-9:30 Pathogenesis of Proliferative Vitreo-Retinopathy
Joint Symposium Euretina & DOG
FR26 Symposium
Moderation:
Sebastian Wolf (Bern)
Gisbert Richard (Hamburg)
This session conveys the most recent knowledge. The discussion
may help to define future research goals. PVR remains a significant
clinical problem. Yet the topic is not well represented in most meetings.
There are no clinically significant advances in dealing with
PVR since the introduction of vitrectomy. Adjunct pharmacological
treatment is barely accepted: Lack of clinical relevance, toxicity,
improper identification of risk factors. Research focuses on "inflammation"
but a key factor similar to "VEGF" in angiogenesis is to be
found. Progress could include: Manageable identification of risk
factors, pharmacotherapy focusing on risk groups, identification of
relevant inflammatory mechanisms.
FR26-167 Current Clinics of PVR
Peter Wiedemann (Leipzig)
FR26-168 Chemokine Levels in Rhegmatogenous Retinal Detachment (RRD)
and their Relation to the Development of Proliferative Vitreoretinopathy
(PVR)
Lukas Ricker, Aize Kijlstra, Fred Hendrikse (Maastricht), Ellen La Heij
(Utrecht)
FR26-169 Galectins – A Future Approach for Treatment and Prophylaxis of
PVR?
Claudia Alge-Priglinger (München)
FR26-170 The Role of Cell Adhesion Molecule Alpha5beta1 Integrin in the
Pathogenesis of PVR
Grit Zahn (Berlin)
FR26-171 The Role of Calcium-Independent Phospholipase A2 in Retinal
Pigment Epithelium Proliferation, Cell Death and Survival
Miriam Kolko (Glostrup)
FR26-172 PVR – Identification of Risk Factors
Sascha Fauser (Köln)
Anterior Chamber Aqueous Flare as a Predictor
for Proliferative Vitreoretinopathy
Sascha Fauser (Köln)
FR26-173 Clinical Adjuvant Treatment with 5-FU
Heinrich Heimann (Liverpool)
FR26-174 Treatment of PVR: Not much Progress
Jan van Meurs, Wim Dik (Rotterdam)
FR26-175 Discussion